Scout | Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)

This opportunity is no longer accepting applications.

grant

Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)

The National Cancer Institute (NCI) is offering a funding opportunity to support the validation of biomarkers and assays used in cancer detection and treatment. The focus is on accelerating the adoption of these tools for various purposes, such as predicting treatment responses and monitoring cancer progression. Applicants must have analytically validated assays suitable for clinical use. The …

Source

Agency: National Institutes of Health

Program: SBIR

Award

Award Ceiling: $250,000

Funding Amount: $250,000

Dates

Opportunity Released: October 31, 2023

Open for Submission: October 31, 2023

Submission Deadline: October 14, 2026

Application Window Closes: October 14, 2026

Keywords

Cancer biomarkers

Assay validation

Molecular markers

Clinical studies

Diagnostic assays

Pharmacodynamic markers

Immunotherapy assays

Clinical laboratory tests

Multi-disciplinary collaboration

Retrospective studies

Supporting Links

Documents

Similar Opportunities

Unlock similar opportunities

Get the full picture on this opportunity

Create a free Scout account to unlock everything you need to decide fast and win the grant.

Instant Fit Analysis

Let our grant expert AI score how well this opportunity aligns with your organization, strengths, gaps, and how to improve your chances of winning funding.
Deep agency & funder detail

Program context, sub-agency structure, and a full eligibility breakdown.
Source links & full documents

Jump straight to the solicitation and download every attachment.
Similar opportunities

Discover related funding matched to your work.

Get a Demo Sign Up

Already have an account? Sign In

Trusted by 500+ Happy Customers